Research ExplorerPublicationsImprovements in Posttransplant Outcomes Over Two Decades in ...

Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study

Standard

Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study. / Bazarbachi, Ali; Labopin, Myriam; Moukalled, Nour; Kröger, Nicolaus; Rautenberg, Christina; Schetelig, Johannes; Finke, Jürgen; Blau, Igor Wolfgang; Blaise, Didier; Stelljes, Matthias; Eder, Matthias; Platzbecker, Uwe; Dreger, Peter; Bethge, Wolfgang; Tischer, Johanna; Burns, David; Sengeloev, Henrik; Brissot, Eolia; Giebel, Sebastian; Nagler, Arnon; Ciceri, Fabio; Mohty, Mohamad.

In: CLIN CANCER RES, Vol. 30, No. 9, 01.05.2024, p. 1778-1787.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bazarbachi, A, Labopin, M, Moukalled, N, Kröger, N, Rautenberg, C, Schetelig, J, Finke, J, Blau, IW, Blaise, D, Stelljes, M, Eder, M, Platzbecker, U, Dreger, P, Bethge, W, Tischer, J, Burns, D, Sengeloev, H, Brissot, E, Giebel, S, Nagler, A, Ciceri, F & Mohty, M 2024, 'Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study', CLIN CANCER RES, vol. 30, no. 9, pp. 1778-1787. https://doi.org/10.1158/1078-0432.CCR-23-3673

APA

Bazarbachi, A., Labopin, M., Moukalled, N., Kröger, N., Rautenberg, C., Schetelig, J., Finke, J., Blau, I. W., Blaise, D., Stelljes, M., Eder, M., Platzbecker, U., Dreger, P., Bethge, W., Tischer, J., Burns, D., Sengeloev, H., Brissot, E., Giebel, S., ... Mohty, M. (2024). Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study. CLIN CANCER RES, 30(9), 1778-1787. https://doi.org/10.1158/1078-0432.CCR-23-3673

Vancouver

Bazarbachi A, Labopin M, Moukalled N, Kröger N, Rautenberg C, Schetelig J et al. Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study. CLIN CANCER RES. 2024 May 1;30(9):1778-1787. https://doi.org/10.1158/1078-0432.CCR-23-3673

Bibtex

@article{8f3b0cf6488347709322b119fda35d0b,
title = "Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study",
abstract = "PURPOSE: Acute myeloid leukemia (AML) is a disease of older patients. Progress in allogeneic hematopoietic cell transplantation (allo-HCT) allowed the delivery of allo-HCT to older patients. We assessed changes over time in transplant characteristics and outcomes in patients with AML ages 65 years and above.PATIENTS AND METHODS: We identified 7,215 patients with AML (median age 68 years, range 65-80) allografted between 2000 and 2021 in first complete remission (CR1; 64%), second or subsequent remission (CR2+; 14%), or active disease (22%).RESULTS: Median follow-up was 40 months. The 3-year cumulative relapse incidence (RI) gradually and significantly decreased from 37% to 31%, then to 30% (P = 0.001) over the three time periods (2000-2009; 2010-2014; 2015-2021), whereas nonrelapse mortality (NRM) decreased from 31% and 31% to 27% (P = 0.003). The 3-year leukemia-free survival (LFS) and overall survival (OS) gradually and significantly improved from 32% to 38%, and then to 44% (P = 0.001) and from 37% to 42%, and then to 49% (P = 0.001), respectively. In multivariate analysis, significant improvement in the RI, LFS, and OS were noted after 2015, whereas NRM was not significantly affected. This improvement was observed regardless of disease status at transplant.CONCLUSIONS: In older patients with AML, we observed an impressive improvement over time in posttransplant outcomes, mostly attributed to decreased RI rather than decreased NRM, and regardless of disease status at transplant. These large-scale, real-world data can serve as a benchmark for future studies in this setting and indicate that the opportunity for transplant for the elderly should be mandatory and no longer an option.",
author = "Ali Bazarbachi and Myriam Labopin and Nour Moukalled and Nicolaus Kr{\"o}ger and Christina Rautenberg and Johannes Schetelig and J{\"u}rgen Finke and Blau, {Igor Wolfgang} and Didier Blaise and Matthias Stelljes and Matthias Eder and Uwe Platzbecker and Peter Dreger and Wolfgang Bethge and Johanna Tischer and David Burns and Henrik Sengeloev and Eolia Brissot and Sebastian Giebel and Arnon Nagler and Fabio Ciceri and Mohamad Mohty",
note = "{\textcopyright}2024 American Association for Cancer Research.",
year = "2024",
month = may,
day = "1",
doi = "10.1158/1078-0432.CCR-23-3673",
language = "English",
volume = "30",
pages = "1778--1787",
journal = "CLIN CANCER RES",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

RIS

TY - JOUR

T1 - Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study

AU - Bazarbachi, Ali

AU - Labopin, Myriam

AU - Moukalled, Nour

AU - Kröger, Nicolaus

AU - Rautenberg, Christina

AU - Schetelig, Johannes

AU - Finke, Jürgen

AU - Blau, Igor Wolfgang

AU - Blaise, Didier

AU - Stelljes, Matthias

AU - Eder, Matthias

AU - Platzbecker, Uwe

AU - Dreger, Peter

AU - Bethge, Wolfgang

AU - Tischer, Johanna

AU - Burns, David

AU - Sengeloev, Henrik

AU - Brissot, Eolia

AU - Giebel, Sebastian

AU - Nagler, Arnon

AU - Ciceri, Fabio

AU - Mohty, Mohamad

N1 - ©2024 American Association for Cancer Research.

PY - 2024/5/1

Y1 - 2024/5/1

N2 - PURPOSE: Acute myeloid leukemia (AML) is a disease of older patients. Progress in allogeneic hematopoietic cell transplantation (allo-HCT) allowed the delivery of allo-HCT to older patients. We assessed changes over time in transplant characteristics and outcomes in patients with AML ages 65 years and above.PATIENTS AND METHODS: We identified 7,215 patients with AML (median age 68 years, range 65-80) allografted between 2000 and 2021 in first complete remission (CR1; 64%), second or subsequent remission (CR2+; 14%), or active disease (22%).RESULTS: Median follow-up was 40 months. The 3-year cumulative relapse incidence (RI) gradually and significantly decreased from 37% to 31%, then to 30% (P = 0.001) over the three time periods (2000-2009; 2010-2014; 2015-2021), whereas nonrelapse mortality (NRM) decreased from 31% and 31% to 27% (P = 0.003). The 3-year leukemia-free survival (LFS) and overall survival (OS) gradually and significantly improved from 32% to 38%, and then to 44% (P = 0.001) and from 37% to 42%, and then to 49% (P = 0.001), respectively. In multivariate analysis, significant improvement in the RI, LFS, and OS were noted after 2015, whereas NRM was not significantly affected. This improvement was observed regardless of disease status at transplant.CONCLUSIONS: In older patients with AML, we observed an impressive improvement over time in posttransplant outcomes, mostly attributed to decreased RI rather than decreased NRM, and regardless of disease status at transplant. These large-scale, real-world data can serve as a benchmark for future studies in this setting and indicate that the opportunity for transplant for the elderly should be mandatory and no longer an option.

AB - PURPOSE: Acute myeloid leukemia (AML) is a disease of older patients. Progress in allogeneic hematopoietic cell transplantation (allo-HCT) allowed the delivery of allo-HCT to older patients. We assessed changes over time in transplant characteristics and outcomes in patients with AML ages 65 years and above.PATIENTS AND METHODS: We identified 7,215 patients with AML (median age 68 years, range 65-80) allografted between 2000 and 2021 in first complete remission (CR1; 64%), second or subsequent remission (CR2+; 14%), or active disease (22%).RESULTS: Median follow-up was 40 months. The 3-year cumulative relapse incidence (RI) gradually and significantly decreased from 37% to 31%, then to 30% (P = 0.001) over the three time periods (2000-2009; 2010-2014; 2015-2021), whereas nonrelapse mortality (NRM) decreased from 31% and 31% to 27% (P = 0.003). The 3-year leukemia-free survival (LFS) and overall survival (OS) gradually and significantly improved from 32% to 38%, and then to 44% (P = 0.001) and from 37% to 42%, and then to 49% (P = 0.001), respectively. In multivariate analysis, significant improvement in the RI, LFS, and OS were noted after 2015, whereas NRM was not significantly affected. This improvement was observed regardless of disease status at transplant.CONCLUSIONS: In older patients with AML, we observed an impressive improvement over time in posttransplant outcomes, mostly attributed to decreased RI rather than decreased NRM, and regardless of disease status at transplant. These large-scale, real-world data can serve as a benchmark for future studies in this setting and indicate that the opportunity for transplant for the elderly should be mandatory and no longer an option.

U2 - 10.1158/1078-0432.CCR-23-3673

DO - 10.1158/1078-0432.CCR-23-3673

M3 - SCORING: Journal article

C2 - 38514469

VL - 30

SP - 1778

EP - 1787

JO - CLIN CANCER RES

JF - CLIN CANCER RES

SN - 1078-0432

IS - 9

ER -